Given that NfL is a neuronal structural component, serum NfL might be a better biomarker for monitoring the degree of neurodegeneration of NMOSD (101–103) and associated cognitive impairment (113) than serum GFAP. This evidence concerns the gene NEFL and Cognitive impairment.